Clarus Therapeutics Holdings, Inc.: going-concern / distress — Clarus Therapeutics completes Chapter 11 liquidation; all common stock cancelled

Clarus Therapeutics Holdings, Inc.

Plan effective Feb 28, 2023; all outstanding common stock cancelled and discharged.
Board of directors dissolved as of the Effective Date.
Company intends to file Form 15 to deregister securities and suspend SEC reporting.
Previously sold JATENZO assets to Tolmar in Oct 2022; sale approved by bankruptcy court.
Clarus will cease periodic reporting obligations upon Form 15 filing.

item 1.03 item 2.01 item 3.03 item 5.01 item 5.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

Clarus Therapeutics Holdings, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2022-09-05).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2022-09-05

Exact text from the filing

Clarus Therapeutics Holdings, Inc., or Clarus, and its wholly-owned subsidiary Clarus Therapeutics, Inc., or OpCo, filed voluntary petitions for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware, or the Court (Case No. 22-10845).

View on SEC.gov

Browse all distress & bankruptcy →

Source: SEC EDGAR

accession 0001213900-23-015846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.